Leveling the Playing Field in Biotechnology Investing

Subscribe to Excellence
Welcome aboard! Your submission has been received and you are now a part of the MedicalGold.ca community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.

Based in Vancouver, Biovaxys Technology Corp. (CNSX: BIOV) is a British Columbia registered, clinical-stage biotechnology company that is developing viral and oncology vaccine platforms for SARS-CoV-2 and various cancers.  The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous cell therapy used in combination with PD1 and PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer.  BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and a patent application for its SARS-CoV-2 (Covid-19) technology.  BioVaxys common shares trade on the CSE under the stock symbol “BIOV.”